Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients With HER2-Positive Advanced Solid Tumors, with an Expansion Cohort in HER2-Positive Metastatic Breast Cancer (MBC)

ONT-380 had lower incidence and severity of diarrhea and rash than that typically associated with current dual HER2/EGFR inhibitors and showed notable anti-tumor activity in heavily pretreated HER2-positive MBC patients.

 Clin Cancer Res